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ABSTRACT OF THE THESIS 
THE OSCILLATORY SHEAR INDEX: QUANTIFICATIONS FOR VALVE TISSUE 
ENGINEERING AND A NOVEL INTERPRETATION FOR CALCIFICATION 
by 
Alexander T. Williams 
Florida International University, 2018 
Miami, Florida 
Professor Sharan Ramaswamy, Major Professor 
 
    Heart valve tissue engineering (HVTE) stands as a potential intervention that could 
reduce the prevalence of congenital heart valve disease in juvenile patients. Prior studies 
in our laboratory have utilized mechanobiological testing to quantify the forces involved 
in the development of heart valve tissue, utilizing a Flow-Stretch-Flexure (FSF) 
bioreactor to condition bone marrow stem cells (BMSCs)-derived valve tissue. 
Simulations have demonstrated that certain sets of flow conditions can introduce specific 
levels of oscillatory shear stress (OSS)-induced stimuli, augmenting the growth of 
engineered valves as well as influencing collagen formation, extracellular matrix (ECM) 
composition and gene expression. The computational findings discussed in this thesis 
outline the methods in which flow conditions, when physiologically relevant, induce 
specific oscillatory shear stresses which could not only lead to an optimized valve tissue 
phenotype (at 0.18≤ OSI≤ 0.23), but could identify native valve tissue remodeling 
indicative of aortic valve disease. 
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1. INTRODUCTION 
1.1 Problem Statement: 
   Heart valve disease remains a prevalent concern in patients with cardiovascular 
disease and pediatric patients with congenital heart defects. Several potential 
interventions can be applied to these patients to mitigate the effects of this condition, 
one of which involves the application of engineered heart valves (EHVs)[1, 2]. For this 
modality, the environment necessary for the appropriate development of engineered 
valve tissue would require a specific set of flow conditions to be met. These flow 
condition regimes have the potential to induce appreciable development and gene 
expression of heart valve tissue [4, 2, 3, 5], with physiological flow conditions 
speculated to significantly enhance EHV phenotype. Recapitulating the biological 
circumstances necessary for conditioning EHVs would then require an understanding of 
the mechanobiological forces crucial to EHV fabrication. Genes, such as klf2a and cd31, 
induce favorable maturation in vascular endothelial cells (VECs), which aid in the 
activation of regenerative processes of heart valve tissue. These genes also induce 
viability in bone marrow stem cells (BMSCs), which were found to be imperative in the 
fabrication of engineered valves. Such genes were found to be present when certain flow 
parameters, such as shear stress, occurred at the tissue level [6, 7].  
   These flow patterns have also been shown to influence valve blood flow mechanics in 
native valve tissue. From a hemodynamical standpoint, abnormal flow physics have 
been shown to progress aortic valve disease by influencing the accumulation of calcified 
plaque deposits along valve leaflets [9, 8, 2, 10]. Further studies have shown that aortic 
valve remodeling is affected by an abnormal flow regime, such as was found with wall 
2 
 
shear stress, which could be an initiator in the process of valve calcification [11]. Based 
on these implications, we hypothesize that the oscillatory flow physics that exist at the 
tissue level would not only indicate gene expression that corresponds to a potential 
optimization in EHV formation and phenotype, but could also act as an indicator for the 
remodeling of the tri-leaflet valve systems in terms of valve calcification. 
1.2   Current Barriers: 
   Extensive research in the fields of biomechanics realize EHV development across a 
gene-tissue hierarchy. In our lab, the research carried out has implemented a simulated 
Flow-Stretch-Flexure (FSF) bioreactor (Fig. 1) to identify the conditions that moderate 
the fluid flow parameters involved in engineering valve tissue. Computational studies 
have shown that there is a 
correlation between oscillatory 
shear stresses and valve 
development, including 
appreciable collagen formation 
and valvular phenotype [5, 12, 13]. These findings suggest that there should then be a 
particular range of oscillatory shear stresses (OSS) that could correspond not only to 
engineered valve tissue augmentation, but also to the expression of genes that sustain the 
architecture and functionality of EHVs. However, the distinct conditions that would 
express these levels of OSS have not yet been determined. Furthermore, there is little 
evidence on whether such conditions would impose similar levels of OSS across an 
appropriate physiologically relevant model, i.e. healthy aortic valve leaflets, or if such 
Fig.1: (a) FSF Bioreactor Chamber schematic [25] used to 
design (b) a simulated bioreactor model modelled on 
ANSYS® CFX 
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conditions derive such OSS levels specifically across the geometric configuration of the 
poly(l-lactic acid) / poly(l-glutamic acid) (PLLA/PLGA) scaffold-based FSF bioreactor 
environment.  
    Retrospectively, since fluid flow is crucial in the facilitation of OSS [14, 6], a 
previous report [12] suggests that a physiologically relevant, vessel-specific flow regime 
could produce a range of OSS, summarized as an oscillatory shear index (OSI) between 
0 and 0.5 (Eq. 1), that is theorized to optimize valvular phenotypic characteristics and 
gene expression specific to EHVs [12].  Considering the ramifications of this study, the 
FSF bioreactor geometry was re-
deployed to simulate physiological 
conditions for identifying flow 
parameters across a typical 
bioreactor environment.  
    There are several flow parameters that could influence the development of valve 
disease in native tri-leaflet valves [9, 2, 15, 16, 17 18, 10]. However, few studies have 
looked at how the remodeling of the valvular ECM environment could be affected by 
OSS-induced stimuli and whether this remodeling could correlate to adverse effects, i.e. 
calcified plaque deposits, which lead to valve disease. Subsequently, physiological 
conditions were prescribed to a healthy heart valve conduit, undergoing mid-diastole, to 
correlate the flow parameters along the scaffolds to those involved with the geometry of 
the valve leaflets when exposed to similar conditions. Additional simulations were run, 
 
𝑂𝑆𝐼 = 0.5 ∙ (1 −
|∫ 𝑊𝑆𝑆 𝑑𝑡
𝑇
0
|
∫ |𝑊𝑆𝑆| 𝑑𝑡
𝑇
0
) 
 
 
Equation 1: Oscillatory Shear Index  
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adding calcified deposits to the heart valve geometry to identify if there were any 
notable variations in the OSI distribution of a diseased valve model geometry.  
1.3.   Specific Aims:  
The hypothesis was tested using the following specific aims:  
Specific Aim 1: Simulating physiologically relevant flow conditions across a 3D-
computational tissue-level environment, and demarcating flow physics across the 
BMSC-layered scaffolds of the model. 
Specific Aim 2: Modelling physiologically relevant flow conditions across heart valve 
models, both healthy and calcified, and distinguishing the flow parameters specific to 
both normal valve hemodynamics and region-defined valve calcification. 
1.4.    Methodologies: 
    To efficiently carry out and run the simulated experiments, an Intel Xeon® X5550 
central processing unit with dual processors (2.66 and 2.667 GHz) was employed due to 
its processing power rendering it capable of maintaining multiple simulations. The study 
also used a Windows® 7 64-bit operating system which met with the software 
requirements necessary from the appropriate simulation software and the graphics that 
coincide with the results.  
   The tissue-based simulations, executed through ANSYS Workbench®2016 (ANSYS 
Inc., Canonsburg, PA) used a set of physiologically relevant, vessel-specific velocity 
profiles (fig.2, 3, 4) prescribed to the inlet of the given geometry. The tissue-based 
simulations used the fluid parameters of cell culture basal media, in which the simulated 
fluid was Newtonian, produced laminar flow, and had both a density of 1.01 g/cm3 and 
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a viscosity of 1.27 cP.  For each simulation run, transient data needed to reach an 
appropriate level of accuracy during the solution phase of each computation, which 
required the convergence criteria to be set to 1 x 10-9 and each given time step, of the 
respective timeframe for each profile, to go through 50 iterations to ensure result 
precision. Computational properties of tissue-level studies, such as the geometry or the 
fluid properties, were validated with previous simulated pulsatile studies.  
     For the valve-based computational geometries, 3D reconstructions of both a healthy 
valve-aortic root (AVAR) anatomy and a diseased AVAR anatomy were modelled 
within SolidWorks ®2015a. Each model was then separately imported into ANSYS 
Workbench®2016, similar to the tissue-based simulations, using the aortic-specific 
velocity profile (fig. 3) as an inlet boundary condition. The simulations used the fluid 
parameters of blood, a non-Newtonian simulated fluid with a density of 1.06 g/cm3 and 
a viscosity of 3.5 cP.  The boundary conditions were employed into the model with an 
80 mm Hg-pressure profile prescribed to the outlet and no-slip boundary conditions 
applied to the overall structure of the model. The valve-based studies were validated by 
computing a 120 mm Hg pressure reading at the inlet when utilizing pulsatile conditions 
across the healthy valve.   
   After collecting OSI and time-averaged wall shear stress (TAWSS) data from the 
tissue-based simulations, the quantifications were compared to data originating from 
shear stress boundary conditions used for shear stress experiments, which were executed 
within a Bioflux 1000 system (Fluxion Biosciences, South San Francisco, CA) for 
BMSCs. Associations between the given parameters were able to determine whether 
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there was a link between the acquired computed data and the genes expressed during the 
shear stress experiments.  
    For the flow quantifications found within this study, the mean and standard error of 
the mean for both cases were given for each parameter used. Statistical differences 
between the simulated data and the experimental data were confirmed using ANOVA 
tests (p<0.05). 
2. LITERATURE REVIEW 
2.1. Heart Valve Disease 
   Heart valve disease has been increasing in incidence in the United States with an 
estimated 1.5 million citizens affected [19]. Some of the symptoms of heart valve 
disease include regurgitation, which involves blood flowing back into the ventricle 
during diastole, and stenosis, which involve occlusions of the valve orifice most 
prominently from the stiffening and thickening of the valves, which can be due to 
calcification. The most common cases of aortic valve stenosis (AVS) occur as calcific 
aortic stenoses, which can be developed with age, and congenital bicuspid aortic 
stenoses, diagnosed at birth [15, 18].  
   AVS, once considered an age-related degenerative condition resulting in the formation 
of calcium deposits in heart valves, has recently been shown to be involved in an 
intricate set of processes similar to atherosclerosis. These processes have been 
demonstrated to damage the valvular endothelial layer due to an increase in mechanical 
stresses, thought to be an initializing event for developing AVS [20, 18].  The flow of 
blood through the aortic valve accounts for these fluid-induced mechanical forces, such 
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as the shear stress across the valves, leading to abnormalities within the cellular 
architecture of both the fibrotic and ventricularis sides of aortic valves, given any 
quantifiable deviations of these fluid-induced forces. 
    VECs, undergoing physiological shear stress values, respond by expressing anti-
inflammatory genes; however, when they are exposed to abnormal fluid flow shear 
stress, inflammatory mediators were activated.  Studies have also shown the activation 
of calcification-related genes after VECs have been exposed to abnormal shear stresses. 
[11, 21]. Though it has been shown that discrepancies in mechanotransductive forces 
and tissue hemodynamics could lead to endothelial damage, these flow field mechanics, 
given normal, healthy circumstances, substantially maintain the environment of 
engineered valve tissue [ 2, 10 ,18-21].  
2.2. Heart Valve Replacement and Repair Procedures 
     2.2.1.  Replacement 
   Heart valve prosthetics have been recognized as a suitable method to replace diseased 
heart valves. Early heart valve prosthetics during early valve prosthetic implantation 
used mechanical heart valves (MHVs). MHVs used in clinical trials had several different 
variants, including the ball-and-cage mechanical valve, the rotating disk valve and 
bileaflet trileaflet mechanical valves. However, MHVs were associated with irregular 
hemodynamics, such as high velocity backflow jets and high shear stresses across hinges 
of the valves, causing hemolytic dysfunction, and requiring patients to take life-long 
anticoagulation medications. [3] 
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   In such cases, bioprosthetic heart valves (BHVs) were developed to better acclimate 
with the environment of the aorta due to its integration of native tissue from animals 
(xenografts), human donors (homografts), or from the patient's body (autografts). The 
main advantage of bioprosthetic heart valves was that patients would not be required to 
take life-long anticoagulants. However, the risk for BHV replacements came from the 
structural valve deterioration that occurred from the narrow durability and stability of 
BHVs, which would then increase the chance for reoperation, particularly for pediatric 
patients [3, 23].  
     2.2.2. Repair 
     Valvular surgery is the other intervention which could be used to treat damaged, 
diseased or calcified heart valves, typically involving open heart surgery. Several 
techniques have been developed for the repair of aortic valves, including the Ross 
procedure, which involves aortic repair utilizing pulmonary valve tissue, and minimal 
access aortic valve surgery through which sutureless valves could potentially improve.   
It is the more ideal choice for severe regurgitation due to valve prolapse, though aortic 
root remodeling could also ultimately be necessary for this type of repair. Foregoing 
valve replacement with repair could sometimes lead to a postoperative revision, though 
the reoperation rate usually occurs between 2-3%, not looking beyond the results that 
occur 10 years post-operation. [24] 
   2.3. Tissue Engineering and Regenerative Methods for Heart Valves 
         2.3.1. Motivation 
   An appropriate potential alternative for replacement of both mechanical and 
bioprosthetic heart valves would involve the use of regenerative approaches to construct 
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tissue engineered heart valves (TEHVs). TEHVs are also associated with a more native 
set of hemodynamics in comparison to mechanical valves, while also having a lower 
potential for reoperation in comparison to bioprosthetic heart valves. Additionally, 
unlike both valve replacement modalities, TEHVs not only have a more natural blood 
flow regime due to their natural structure, but they have the capability to grow with the 
patient, making them suitable for pediatric patients [4, 1, 25].  
       2.3.2.  Challenges 
      There are several pitfalls that need to be addressed involving the construction of 
TEHVs, and consequently restricting their use within the clinic. TEHVs, though 
biocompatible, have been shown to undergo complications at the cellular level, in which 
interstitial and endothelial cells have limited communication between the extracellular 
matrix. Additionally, TEHVs are also subject to flow physics used for conditioning in 
controlled environments (i.e., bioreactors) that can vary to the physiological blood flow 
physics associated with native valves [4, 3]. Particularly with decellularized TEHVs, 
there is also the threat of valvular deterioration that could be caused from inflammatory 
rejection [4].  
   2.3.3.   Literature Review of the Field 
  There have been several approaches taken for the scaffolding and succeeding 
development of TEHVs, such as in the study by Konertz et al .[26], which involved 
implanting a decellularized porcine aortic valve xenograft into several patients (age 
median: 46 years) throughout a two-year timeframe, with the typical recellularization 
timespan ranging within four months. The results of the study revealed that the valves 
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demonstrated similar characteristics to native healthy valves, particularly due to 
sustaining low, consistent transvalvular gradients [26]. 
     Zhou et al. [27] performed polyethylene glycol (PEG)-ylation of decellularized aortic 
porcine valves. Mechanical testing revealed that there was a significant increase in the 
tensile strength of the aortic valve tissue. The study also looked into using branched 
PEG to facilitate the conjugation of bioactive agents, such as vascular endothelial 
growth factor (VEGF), onto the aortic valve. Human umbilical vein endothelial cells 
(HUVECs) were found to grow appreciably on the tissue when conjugated with VEGF 
and glycine-arginine-glycine-aspartate-serine-proline-cysteine (GRGDSPC) peptides 
after PEG-ylation. 
     Schmidt et al. [31] developed a method for minimally invasive surgery of TEHVs 
using bioreactor technology and adult stem cells. The trileaflet valves were integrated 
onto self-expanding stents and implanted into sheep. In vivo functionality and 
composition analyses revealed newly formed valve tissue with the extracellular matrix, 
producing higher levels of collagen and glycosaminoglycans than typically found in 
native tissue. A similar study was done by Weber et al [28], in which marrow stromal-
cell-based, autologous TEHVs were fabricated. Then, using Nitinol-based stents, these 
TEHVs were implanted into nonhuman primates as pulmonary valves, with composition 
and biomechanical analyses demonstrating that the biodegradable scaffold matrix was 
being replaced with endothelialized, layered, living tissue.  
    Syedain et al. [29] applied an off-the-shelf engineered valve within sheep, which 
resulted in endothelialization, colonization of interstitial-like cells within the engineered 
matrix, new extracellular deposits, such as elastin, retained functionality, and increased 
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tissue remodeling 24 weeks after implantation with no calcification. The structural 
integrity was also deemed satisfactory according to the number of fatigue cycles the 
valve overcame within the time span (17 million cycles).   
   Engelmeyer et al.[14] created a Flow-Stretch-Flexure (FSF) bioreactor using 
mechanical stretching and bending of rectangular, nonwoven 50:50 blend poly (glycolic 
acid) (PGA) and poly(l-lactic acid) (PLLA) scaffolds to condition and optimize the 
development of bone marrow-derived mesenchymal stem cell (BMSC)-derived TEHVs. 
Using two mechanical stimuli physiologically relevant to heart valves, the cyclic flexure 
rate of the samples coupled with a laminar flow regime [Flex-Flow], the results of this 
study reported high levels of tissue formation, collagen content and effective stiffness 
similar to that of smooth muscle cell (SMC)-seeded scaffolds.  
    Ramaswamy et al [25] subsequently tested the validity of using physiological flow, 
stretch and flexure by developing a novel FSF bioreactor for BMSC-derived TEHVs. As 
opposed to the study, which looked at the effects of Flex-Flow conditions in optimizing 
engineered valve growth, the study by Ramaswamy et al. utilized physiologically 
relevant shear stress ranges (5-6 dynes/cm2), leading to higher levels of collagen content 
compared to the levels found in Engelmeyer et al., which induced lower, sub-
physiological shear stress ranges. Furthermore, computational analyses done by Salinas 
et al. [6] and Salinas and Ramaswamy [6] identified the flow-mediated mechanics that 
took place within the confines of an FSF bioreactor environment. Specifically, fluid-
induced oscillatory shear stresses were found to be substantial in the conditioning of 
TEHVs. 
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a. 𝜌 (
𝜕𝑢
𝜕𝑥
+ 𝑢 ∙ ∇𝑢) = −∇ ∙ 𝑃 + 𝜌𝑔 + 𝜇 ∙ ∇2𝑢 
 
b. ∇𝜌 = 0 
Equation 2: The Navier Stokes equation represented 
by the momentum equation (a) and the continuity 
equation (b) 
 
       2.4.  Computational Fluid Dynamics (CFD) and Heart Valve Tissue Engineering     
          2.4.1. CFD and Heart Valves  
     Tissue-based computational 
analysis, employing the Navier-
Stokes Equations for continuity and 
momentum (Eq. 2), has been 
utilized in studies involved with determining the flow physics and mechanical forces 
that occur across heart valves. Such analyses have also been applied within other 
domains in which valvular tissue is grown and conditioned (i.e., bioreactors). Previous 
computational studies have shown that native hemodynamics have certain levels of 
shear stresses that are imposed on aortic valve tissue, particularly at a range of 0 to 3.49 
dynes/cm2 [30].  
             2.4.2. Previous Studies in Our Laboratories 
                   2.4.2.1. Flow systems 
                          2.4.2.1.1.  Flow-Stretch-Flexure Bioreactor 
  We have utilized an FSF bioreactor, which seeds human bone marrow stem cells across 
scaffolds that undergo certain degrees of flexure and bending, along with supplying a 
flow regime across the bioreactor chambers, to provide the mechanical forces necessary 
to sustain and even enhance the development of heart valve tissue. With a need to 
understand and control the flow physics that impart these mechanical forces across 
scaffolds to optimize the quality, phenotype, and growth of engineered heart valves, 
employing computational modelling and analysis of the flow conditions, including 
ANSYS Workbench ®2016 and Tecplot 360 EX ®2016, provide a sufficient segue to 
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resolve this matter. In regard to the mechanical forces that are analyzed within these 
studies, principally, we have found that OSS, which oscillate due to the fluctuating of 
flow back and forth, can supplement the development of valvular tissue. Our laboratory 
has looked at the different sets of flow conditions within the bioreactor geometry, 
retaining certain values of oscillatory shear stresses, summarized as OSI, which range 
from 0, indicating no oscillating shear patterns, to 0.5, indicating high levels of 
oscillatory shear stresses.    
                     2.4.2.1.2. Shear Stress Cell Assay System (Bioflux) 
      Studies within our lab have used the Bioflux 200 system to condition individual 
cells, or groups of cells, by using shear stress profiles to recapitulate multiple conditions 
before analyzing the cells’ behavior, gene expression patterns, and morphology. Shear 
stress plates previously used have had an applicable shear stress range of 0-20 
dynes/cm2. 
                2.4.3. Steady Flow 
     Steady-state flow conditions set different cases where the scaffolds were flexed at 
varying conformations. When utilized within simulations, results revealed that there was 
little to no oscillatory flow (OSI=0) across the tissue specimens when the scaffold was at 
constantly straight  configurations [6]. Shear stress averages were found to be 1.98 
dynes/cm2 at the inner walls, and 2.43 dynes/cm2 at the outer walls [5]. 
            2.4.4. Cyclic Flexure and Steady Flow (Flex-Flow) 
    Flex-Flow conditions used a steady-state flow regime coupled with cyclic flexing of 
the samples at the physiologically relevant frequency of 1 Hz. Results demonstrate that 
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the OSI=0.11 at the inner walls of the samples and OSI=0.09 at the outer walls averaged 
out to an OSI=0.10. Shear stress averages were found to be 2.91 dynes/cm2 at the inner 
walls and 4.73 dynes/cm2 at the outer walls. Use of Flex-Flow showed improved 
collagenous formation and optimized expression of genes involved with valvular 
development such as Klf-2a and Cdz-1 [5]. 
          2.4.5. Non-Physiological Pulsatile Flow (NPFF) 
          A square-wave, non-physiological flow regime was prescribed to the inlet of the 
bioreactor system. When utilized within simulations, results revealed that there was high 
oscillatory flow with an OSI=0.45 at the inner walls and an OSI=0.29 at the outer walls 
averaged out to OSI=0.37. Shear stress averages were shown to be 1.5 dynes/cm2 at the 
inner walls and 1.2 dynes/cm2 at the outer walls. When used in experiments, NPFF 
conditions had similar rates of collagenous development and expression of Cdz-1 
compared to the Flex-Flow case, but sustained a statistically significant decrease in the 
expression of Klf-2a [12]. 
3.  SPECIFIC AIM 1 
      Young patients born with critical congenital valve diseases are faced with a grim 
prognosis.  Prosthetic valves, while a mature technology, do not cater to the small size of 
these patients, nor can they enable somatic growth.  Towards the development of 
functional tissue engineered heart valves (TEHVs) several protocols have been 
investigated in an effort to optimize physical, mechanical, and biochemical properties [2, 
22, 31].  Regardless of the specific approaches, gene, cellular, and tissue-level responses 
of the TEHV are intimately tied to the mechanical environment native to the 
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cardiovascular system [2, 23, 32, 12]. Recently, the directionality of fluid-induced shear 
stress, i.e., oscillatory shear stresses, have been shown to be essential in heart valve 
tissue development including cellular proliferation, extracellular matrix (ECM) 
production, and the overall preservation of the valvular phenotype [33–35].   In an in 
vivo model, Vermot et al established a link between OSS and its direct regulatory role 
on the critical gene KLF2A, whose absence results in heart valve defects [7].  In our 
laboratories, as well as elsewhere, in vitro mechanical environments that elicit OSS, 
such as Flex-Flow or pulsatile flow, demonstrated clear merits of engineered 
extracellular matrix (ECM) collagen production and valvular phenotype derived from 
human bone marrow mesenchymal stem cells (HBMSCs) [14, 5, 12]. In particular when 
the mechanical conditions were in the physiological range (fluid shear stresses of 4-5 
dynes/cm2 and cyclic flexure frequency of 1 Hz), de novo tissue content was further 
augmented, with relatively-high presence of genes supporting the cardiovascular 
phenotype, including robust KLF2A expression [5]. On the other hand, use of a NPPF 
condition adversely impacted KLF2A expression, although other pertinent genes (such 
as FZD2) and overall ECM collagen content remained unaffected.  Regardless of the 
specific mechanical conditions used, the common underlying thread in studies where 
tissue construct biological properties were substantially improved in comparison to static 
culture, was the exposure of BMSC-derived engineered tissues to OSS.  Indeed, we 
previously established that OSS plays a critical role in the formation of engineered heart 
valve tissues when the magnitude of fluid-induced shear stresses is physiologically 
relevant [12].  In this investigation, we wanted to identify the specific value(s) of fluid 
oscillations rather than the shear stresses that led to these enhanced properties.  He and 
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Ku [20] have shown that the fluid oscillations can be quantified using the oscillatory 
shear index (OSI) (Eq. 1). 
    Utilizing physiologically relevant hemodynamic conditions from different vascular 
sources, here, we took a computational approach towards determining a range of OSI 
that may be important in enhancing gene, cell, and tissue-level properties in TEHVs. 
Subsequently the effect of physiologically relevant OSI versus non-physiological OSI, 
either too high or too low, was evaluated experimentally in HBMSC culture 
experiments. 
3.1. Methodology of Specific Aim 1 
All simulations in this study were carried out using commercially available software 
(ANSYS® Workbench 2016, Ansys Inc., Canonsburg, PA) within a Windows® 7 64-bit 
Operating System environment (Microsoft Inc., Redmond, WA).  A workstation with 
dual processors was used to facilitate an efficient and accurate solution convergence 
(Intel Xeon® X5550, 2.66 GHz processor speed, Intel Inc., Santa Clara, CA).       
     The simulations comprised a geometry depicting a flow-stretch-flexure (FSF) 
bioreactor which has been used to conduct several tissue engineering experiments in our 
laboratory [25, 5, 6, 12]. The bioreactor chamber consists of a U-shaped flow path, with 
a diameter of 13 mm. Recognizing the significance of wall shear stress induction 
regarding heart valve tissue development, there have been several cases of flow rate that 
have been analyzed in the application to the FSF bioreactor, including static, steady-
state, pulsatile square waveform, cyclic flexure, and Flex-Flow cases.  
    For each physiologically relevant pulsatile flow simulation that was run, a no-slip 
boundary condition was assigned to the walls of the bioreactor while a porous fluid 
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interface was prescribed to the surfaces of each rectangular-shaped scaffold (n = 3 
specimens per flow chamber; specimen dimensions: 17 mm x 6.5 mm x 1 mm).  Three 
pulsatile flow simulations were conducted; specifically, the inlet pulsatile velocity 
boundary conditions from two arteries (pulmonary artery (Fig. 2) and aorta (Fig. 3)) 
[Lotz et al. 2002] and one vein (superior vena cava (Fig. 4)) [36] were used. A zero-
pressure boundary condition was prescribed at the outlets. All simulations utilized fluid 
material properties of basal cell culture media consisting of a density of 1.01 g/cm3 and a 
dynamic viscosity of 1.27 cP [6].  Solution convergence was interpreted to have 
occurred when residuals arising from the continuity and momentum equations were able 
to meet a prescribed convergence criterion of 1 x 10-9. 
 3.1.1. Inlet and Outlet Boundary Conditions 
   For the following simulations, three physiological boundary conditions [36] were 
separately prescribed across the bioreactor inlet while a zero-pressure boundary 
condition was prescribed to the outlet.  
           3.1.1.1. Pulmonary Arterial Waveform 
 
Figure 2: Pulmonary arterial waveform with peak velocity at 0.095 m/s and a mean velocity at 
0.022 m/s 
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3.1.1.2. Aortic Waveform 
 
 
3.1.1.3. Superior Vena Caval Waveform 
 
        
 
Figure 4: Superior vena caval waveform with peak velocity at 0.025 m/s and a mean velocity at 0.0081 
m/s. 
 
Figure 3: Aortic waveform with peak velocity at 0.109 m/s and a mean velocity at 0.0241 m/s. 
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3.1.2. Numerical Independence 
     Independence testing was carried out to optimize the computational conditions as 
follows: 
      3.1.2.1. Mesh Independence 
     A bioreactor geometry mesh that we had previously utilized for computational 
investigations [6] was used as the basis for the current study (Fig. 5).  The optimized 
quadrilateral meshing density for the geometry consisted of 441,000 elements and 
472,000 nodes. Use of this mesh in a steady flow simulation in comparison to our 
previous work [13] yielded a mean specimen wall shear stress (n = 3 specimens) that 
was within a 5% margin of agreement.  
 
      3.1.2.2. Timestep Independence  
  The pulmonary artery computational fluid dynamics (CFD) simulation was used as the 
basis to select a valid time-step for all simulation cases.  A time-step of 1 ms yielded a 
low Courant number (< 1.00) suggesting that it would permit temporal accuracy in 
Figure 5: The FSF bioreactor quadrilateral mesh as shown from both the xz-axis (a) and the yz-axis 
(b). The mesh density of the geometry was optimized at 4.72x105 nodes and 4.41x105 elements with 
the mesh refined around the samples of the bioreactor, as depicted from the xz-axis (c) and the xy-axis 
(d) with the black arrow pointing to the proximal wall of each respective sample and the purple arrow 
pointing to the distal wall.  
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resolving the flow computations. However, to facilitate efficiency in computation times 
for solution convergence, the time-step was gradually increased (2 ms and 3 ms) to 
determine if a solution was possible to within 5% error of the solution derived from the 
1-ms time-step case.   Eventually, a 2-ms time-step was chosen based on its resulting 
time-averaged specimen shear stress prediction (n = 3 specimens), which was found to 
be within 5 % of the value obtained for the 1 ms time step simulation.  
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   3.1.2.3. Cyclic Independence 
     In the pulmonary artery CFD simulation the time-averaged specimen wall shear 
stresses (n =3) of the 1st and 2nd cycles were compared to their corresponding value in 
the 3rd cycle.  Both the 1st and 2nd cycles yielded values that were within 1% of the 
time-averaged specimen shear stress value obtained from the 3rd cycle.  Therefore, all 
results presented in this study were taken from the 2nd cycle. 
          3.1.3. CFD Validation  
  Results in the current study from the pulmonary artery pulsatile flow simulation 
utilizing a structured, quadrilateral mesh were compared to a previously well-established 
pulsatile flow simulation from our laboratory which used a tetrahedral, unstructured 
mesh [13].  Again, the computed time-averaged specimen wall shear stress metric was 
used as the basis for the comparison. The time-averaged specimen shear stress from the 
structured mesh was found to be within 5% of the value from the unstructured mesh.  
       3.1.4 Mechanobiological Testing 
       First, additional FSF bioreactor simulations were performed using a set of 
prescribed velocity waveforms (Fig. 6a) which produced time-averaged shear stress 
profiles (Fig. 6b) that were subsequently used to compute three OSI-values representing 
low (OSI = 0.10), high (OSI = 0.38) and the sweet-spot (OSI = 0.23) ranges.  The 
physiologically relevant and high OSI were obtained from the distal wall of the 
specimen and low OSI from the proximal wall.  
Figure 6: Velocity waveforms (a) that produced corresponding shear stress profiles (b) to obtain a (i) 
physiologically relevant OSI (OSI = 0.23) (ii) low-OSI (OSI = 0.10) and (iii) high-OSI (OSI = 0.38). 
Both (i) and (ii) show velocity waveforms and shear stress profiles at magnified scales, as indicated by 
black arrows. 
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     Next, in cell culture experiments, ~ 1 million HBMSCs (Fisher Scientific, Pittsburgh, 
PA) were cultured up to passage 4 (P4). Cells between P4-P6 were subsequently utilized 
and plated in bovine-derived fibronectin (Sigma Aldrich St. Louis, MO) coated 
microfluidic channels and were subjected to three different OSI groups using a 
commercially-available shear stress cell assay system available in our laboratory 
(Fluxion Biosciences, South San Francisco, CA; Martinez et al. 2012). HBMSCs were 
subjected to a 48-hour conditioning cycle and were subsequently processed for RNA 
isolation. A fourth group, a “No flow” or HBMSCs grown in static culture conditions, 
was used as a control.  Each group comprised of 4 samples, where each sample was 
pooled from 2 microfluidic channels. 
         
 
3.1.5. Gene Expression Analysis 
  After 48-hours of conditioning, HBMSCs were subjected to gene expression 
assessment. In brief, total RNA was isolated according to manufacturer’s protocol 
(RNeasy Micro kit, Qiagen) and was quantified using NanoDrop 2000c 
spectrophotometer (Thermo Fisher Scientific, Pittsburgh, PA). 200ng of total RNA was 
Table 1: Quantitative real-time polymerase chain reaction primer sequences for gene expression analysis of 
HBMSCs. 
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used for the cDNA synthesis RevertAid First Strand cDNA Synthesis kit (Thermo 
Fisher, Waltham, CA). The primers (Table 1) were designed using Primer3 software and 
gene sequences were obtained from Basic Local Alignment Search Tool (BLAST) 
program, National Center for Biotechnology Information (NCBI). Quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed using a commercially available 
kit Maxima SYBER Green/ROX qPCR Master Mix (Thermo Fisher Scientific, 
Pittsburgh, PA). Signals were detected with the Step-One Real-Time PCR System 
(Applied Biosystems). The change in cycle threshold (Ct) values were averaged and 
normalized with GAPDH, an endogenous gene using the Ct method [Schmittgen and 
Livak 2008]. Untreated HBMSCs were used as a control for data analysis. 
         3.1.6. Statistical Analysis 
  Shear stress and OSI findings on housed-bioreactor specimens (n=3) were presented as 
the mean ± standard error of the mean (SEM). An ANOVA analysis was performed for 
the 5 groups compared, namely, the three physiologically relevant pulsatile flow cases 
conducted here, and from the previously performed Flex-Flow [5] and NPPF 
[12]studies. A Tukey’s post hoc test was conducted followed by a one-way ANOVA to 
assess any significance between the groups (SPSS, V16, IBM, Armonk, NY). A 
statistically significant difference between groups was determined to have occurred 
when p < 0.05. 
            3.2.  Results of Specific Aim 1 
3.2.1. Velocity Streamlines 
    Velocity contours were taken from cross-sectional planes of the bioreactor across the 
proximal and distal walls of the scaffolds (fig. 7-9). In verifying of proper coupling of 
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the profile to the inlet of the bioreactor, the contours of the planes for each time point 
follow in accordance with the acceleratory and deceleratory phases of the waveform for 
each profile case. The bottom plane, where the distal walls are taken into account, has a 
notably higher velocity distribution than the top plane of each profile case. 
 
       3.2.1.2. Pulmonary Artery 
 
 
 
 
 
 
 
 
Figure 7: Instantaneous velocity contours of the pulmonary arterial profile under five 
equitemporal time points from both the top plane (proximal walls) and the bottom plane (distal 
walls). Peak velocity is distinguished at the peak of the waveform at 0.16 s. 
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3.2.1.2. Aorta 
       
                
     
 
 
 
 
 
 
 
 
Figure 8: Instantaneous velocity contours of the aortic profile under five equitemporal time points 
from both the top plane (proximal walls) and the bottom plane (distal walls). Peak velocity is 
distinguished at the peak of the waveform at 0.16 s.  
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       3.2.1.3. Superior Vena Cava 
 
 
   3.2.2. Vorticity Plots 
     Vortices and eddy currents were quantified on cross-sectional contour planes 
intersecting across the middle of the second scaffold within the bioreactor (Fig. 10-12). 
Trends in high magnitude vortices were observed notably around the scaffold juncture of 
the contour maps for each profile case analyzed with peak magnitude vorticity densities 
occurring during the deceleratory phase of each profile case, when flow reversal would 
start to manifest. 
Figure 9: Instantaneous velocity contours of the superior vena caval profile under five 
equitemporal time points from both the top plane (proximal walls) and the bottom plane (distal 
walls). Peak velocity is distinguished at the peak of the waveform at 0.12 s.  
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3.2.2.1. Pulmonary Artery
 
 
 
 
 
 
 
 
 
Figure 10: Sample-intersecting vorticity contour maps of the pulmonary arterial profile at seven 
time points.  
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3.2.2.2. Aorta 
 
 
 
 
 
 
 
 
 
 
Figure 11: Sample-intersecting vorticity contour maps of the aortic profile at seven time points.  
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3.2.2.3. Superior Vena Cava 
 
 
 3.2.3. Instantaneous Axial Wall Shear Stress Approximations 
      The spatial distributions of shear stresses were presented for both the distal and 
proximal walls of the bioreactor specimens at the specific time points of the cardiac 
cycle (Fig. 13-15).  The cardiac cycle durations for the pulmonary artery, aortic, and 
superior vena cava were 1.08 s, 1.05 s and 1.08 s respectively [Lotz et al. 2002]. In all 
Figure 12: Sample-intersecting vorticity contour maps of the superior vena caval profile at seven 
time points.  
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simulations carried out, maximum specimen shear stresses corresponded with the peak 
temporal position of the prescribed pulsatile velocity profile as expected. Also in 
general, shear stresses were higher on the distal side of the specimens as compared to the 
proximal side. 
        3.2.3.1. Pulmonary Artery 
     In the pulmonary artery case, during the early acceleration phase (t = 1.08 s) of the 
cardiac cycle, the resulting shear stresses were not uniformly distributed (Fig. 13).  
However sufficient inertial forces at a time instance (t = 1.12 s) proximal to the peak 
velocity temporal position enabled higher shear, streamlined laminar flow.  During the 
latter stages of flow deceleration, reversal of flow was observed (at t = 1.36s). 
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3.2.3.2 Aorta 
   The aortic velocity waveform-derived specimen shear stress distributions evolved 
similarly to the pulmonary artery case (Fig. 14). However, the aortic shear stresses 
increased in magnitude more rapidly, reaching a maximum value at t =1.20 s as opposed 
to the pulmonary artery simulation (t = 1.24 s); similarly, noticeable flow deceleration 
effects on specimen shear stress were occurred sooner in the aorta (at t =1.32 s 
comparing Fig 3a to 3b). 
Figure 13: Instantaneous sample shear stress contours for pulmonary arterial simulation. For time 
points 0.00 s, 0.04 s, 0.08 s, 0.16 s, 0.24 s, 0.28 s and 0.32 s, the shear stress averages were 0.08 ± 
0.002, 0.46 ± 0.009, 1.8 ± 0.02, 2.5 ± 0.02, 1.3 ± 0.01, 0.76 ± 0.009 and 0.28 ± 0.007, 
respectively.   
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3.2.3.3. Superior Vena Cava 
    As would be expected, the bulk specimen shear stress ranges were considerably lower 
in venous flow conditions (Fig. 15) as opposed to arteries (Fig. 13 and 14). Multiple 
temporal positions at and beyond the mid-point of the deceleration phase (t =1.36 s) 
revealed substantial flow disturbances as well as flow reversal from the principal flow 
direction.   
Figure 14: Instantaneous sample shear stress contours for aortic simulation. For time points 0.00 
s, 0.04 s, 0.08 s, 0.16 s, 0.24 s, 0.28 s and 0.32 s, the shear stress averages were 0.21 ± 0.003, 0.59 
± 0.006, 2.0 ± 0.02, 2.7 ± 0.02, 1.2 ± 0.01, 0.49 ± 0.009, and -0.06± 0.008, respectively. 
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    3.2.4. Oscillatory Shear Stresses 
     OSI distributions for both the proximal and distal walls were plotted (Fig. 16) for all 
three CFD simulation cases of physiologically relevant pulsatile flow and compared to 
our previous findings utilizing a non-physiological square waveform [12] and a 
combination of physiological-scales of cyclic flexure (1 Hz) and steady flow (Flex-
Flow; flow rate of 850 ml/min) [5, 6]. The overall OSI (Mean ± SEM) for the entire 
Figure 15: Instantaneous sample shear stress contours for superior vena cava simulation. For time 
points 0.04 s, 0.08 s, 0.12 s, 0.20 s, 0.28 s, 0.32 s, and 0.36 s, the shear stress averages were 0.024 
± 0.0003, 0.043 ± 0.0004, 0.057 ± 0.0004, 0.047 ± 0.0003, 0.017 ± 0.0002, 0.004 ± 0.0002, and -
0.003 ± 0.0002 respectively. 
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specimen (n =3; i.e., considering both proximal and distal sides) for the pulmonary 
arterial, aortic, superior vena cava, square pulsatile, and Flex-Flow conditions were as 
follows: 0.23 ± 0.002, 0.18 ± 0.002, 0.19 ± 0.001, 0.37 ± 0.021, and 0.1055 ± 0.052, 
respectively.  Therefore, the range of OSI was found to be: 0.18 ≤ OSI ≤ 0.23 across the 
three physiological pulsatile flow waveforms investigated.  This range was found to be 
significantly lower and higher to non-physiological and non-pulsatile flow-induced OSI 
(Flex-Flow) cases respectively (p < 0.05). 
 
        
 
 
Figure 16: OSI contours (n=3) of the samples housed within the FSF bioreactor. The mean OSI of 
the distal walls for the pulmonary arterial, aortic, superior vena cava, square wave, and Flex-Flow 
conditions were 0.28 ± 0.002, 0.25 ± 0.002, 0.27 ± 0.001, 0.45 ± 0.023, and 0.117± 0.003, 
respectively. On the other hand, the corresponding mean OSIs for the proximal wall were as 
follows: 0.18 ± 0.002, 0.10 ± 0.002, 0.11 ± 0.001, 0.29 ± 0.019, and 0.094± 0.10, respectively. 
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 3.2.5. Analysis of Gene Expression  
     A significantly higher expression (p<0.05) of valve developmental genes KLF2A and 
BMP2, as well as significantly greater up-regulation (p < 0.05) of endothelial and 
activated interstitial markers CD31 and α-SMA respectively, were found in the 
physiologically relevant “sweet-spot” OSI samples in comparison to the low and high 
OSI groups (Fig. 17a). On the other hand, the expression of the bone or calcification 
marker, osteocalcin was statistically insignificant (p > 0.05) between the three groups 
(Fig 17b).     
     NOTCH1, a valve development gene, was significantly down-regulated (p < 0.05) in 
the low OSI group as compared to the high OSI and physiologically relevant “sweet-
spot” OSI groups, which were both modestly up-regulated (Fig 17c). In addition, there 
was significant down-regulation of TGFb1 (associated with valve calcification) in the 
low and “sweet-spot” OSI groups (p < 0.05) in comparison to their high OSI 
counterpart, which was upregulated. Finally, no statistically significant differences (p > 
0.05) were observed in the VCAM1 expression, a known inflammatory marker (Fig. 
17a). 
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         3.3. Discussion of Specific Aim 1 
    Bioreactor-based mechanical conditioning experiments have shown that Flex-Flow 
conditions and square pulsatile conditions lead to enhanced matrix development and 
valve phenotype compared to either steady state flow or cyclic flexure alone [14, 5, 12].  
Coupling of cyclic flexure and steady flow conditions augments regional specimen 
oscillatory shear stresses. Studies have demonstrated the critical link between oscillatory 
shear stress and valve development, whose absence leads to down-regulation of key 
valvular genes, such as KLF2A, thereby resulting in heart valve defects [7].  The 
Figure 17: Gene expression following 48 hours of HBMSCs exposed to low OSI (OSI = 0.10), high 
OSI (OSI = 0.38), and physiologically relevant “sweet-spot” OSI (OSI = 0.23). Error bars are displayed 
as ± SEM; (n=4 samples/group). (a) A statistically significant (p < 0.05) expression of CD31, -SMA 
was found in the physiologically relevant OSI-treated group as compared to the low and high OSI 
counterparts. (b) A significantly higher expression (p < 0.05) of BMP2 was also observed in the 
physiologically relevant OSI groups as compared to the other two groups. No significant differences (p 
> 0.05) were found to occur in the expression of osteocalcin between the groups. (c) KLF2A and 
NOTCH1 genes exhibited a significantly higher expression (p < 0.05) in the physiologically relevant 
OSI group.  Finally, TGFb1 was significantly down-regulated in the low OSI and physiologically 
relevant groups (p < 0.05) in comparison to high OSI-treatment wherein it was upregulated.  
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mechanisms of gene regulation are not fully delineated; however, it has already been 
shown that oscillatory flow-induced stimulus activates mechanosensitive ion channels 
which lead to gene expression critical in valvulogenesis [37].  This indicates that the 
localized condition surrounding the valve that necessitates development requires an 
oscillatory flow component.  Specifically, OSS-mediated cell stimulation of KLF2A 
occurs via the trpv4 and trpp2 calcium channels [37]. We have since shown that the OSI 
can be used as a single metric that co-relates with benefits in specimen properties 
observed from stem cell-derived heart valve tissue engineering experiments [6]; 
Moreover, oscillatory shear stress environments can be mediated through pulsatile flow-
alone without the need for flexing specimens [13].  In the present investigation, we 
hypothesized that healthy valve tissues are exposed to a distinct range of OSI, which 
may be important in maintaining homeostasis, i.e., an OSI “sweet-spot”.   
     Work we conducted previously using square pulsatile conditions [12] within the same 
flow-stretch-flexure bioreactor exhibited an OSI of 0.29 ± 0.019 on the proximal wall 
and an OSI of 0.45 ± 0.023 on the distal wall surface (Fig. 16), with an overall specimen 
OSI average of 0.37 ± 0.021. This indicated significantly higher (p < 0.05) oscillatory 
shear stresses compared to OSI derived from physiological flow profiles, which was in 
the order of 0.18 to 0.23.  In addition, this range of OSI was determined across 3 distinct 
blood vessel flow profiles (pulmonary artery, aorta and superior vena cava).     
   The context of this narrow OSI range (0.18 ≤ OSI ≤ 0.23) is important given that 
higher oscillatory shear stresses fail to promote upregulation of key valvular genes 
(again, such as KLF2A), although this does not appear to alter collagen concentration in 
in-vitro grown engineered tissues [5].  We speculate that phenotype is highly regulated 
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by the specific oscillatory shear stress environment (and likely ideal when within the 
OSI “sweet-spot” range), whereas the ECM content may not as drastically effected by 
OSI magnitude.  To obtain direct evidence of mechanical conditioning effects on 
HBMSCs using a “sweet-spot” value of OSI, we were subsequently able to demonstrate 
experimentally that an OSI = 0.23 led to maximum expression (relative to lower (OSI = 
0.10) and higher OSI (OSI = 0.38) values; Fig. 17) of the valve developmental genes 
BMP2 and KLF2A. The context of this narrow OSI is important given that higher 
oscillatory shear stresses failed to promote up-regulation of key valvular genes.  KLF2a, 
an athero-protective transcription factor, is released by endothelial cells, thereby 
preventing abnormal ECM due to inflammation during valve morphogenesis [37, 7].  
BMP2 is involved during the very early stages of myocardial development and is 
involved in several vital functions during endocardial cushion formation, including 
ECM synthesis and tissue growth as well as initial mesenchymal cell proliferation and 
differentiation to promote the valvular phenotype [38–40]. Moreover, exposure of 
HBMSCs to the sweet-spot OSI range (OSI = 0.23) led to significant (p< 0.05) up-
regulation of phenotypic markers CD31 (endothelial) and α-SMA (interstitial) indicative 
of enhanced HBMSC differential capacity in vitro as compared to corresponding 
exposure to relatively lower (OSI = 0.10) and higher (OSI = 0.38) OSI values.   
Collectively, the primary biological significance of the “sweet-spot” OSI identified here 
is to enhance in vitro gene expression and phenotype in HBMSC-based heart valve 
tissue engineering using a clearly quantified narrow range of OSI values as opposed to 
utilizing a random selection of oscillatory flow magnitudes. 
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     Conversely, Flex-Flow conditions (1 Hz cyclic flexure combined with steady flow 
spatial mean specimen shear stress of 5 dynes/cm2)  previously resulted in a distal OSI 
of 0.117 ± 0.003, a proximal OSI of 0.094± 0.10 and  an overall specimen OSI of 0.106 
± 0.052 [5].  While both the cyclic flexure and shear stress magnitudes were 
physiologically relevant, the net OSI was not since it was significantly smaller (p < 0.05) 
than the OSI "sweet-spot" determined here.  The biological implications of exposing 
engineered valve tissues to physiologically relevant scales of OSI is not entirely clear; 
however, incorporation of oscillatory shear stresses has augmented phenotype and ECM 
content under previous Flex-Flow conditions [5]. Here, we have found via performing 
OSI-based HBMSC experiments, that this can be further improved if the OSI can be 
moved to within the physiological range, i.e., the “sweet-spot” that was identified here.  
The bioreactor system which we utilized is able to mimic regionally varying shear 
stresses on the specimen surfaces and is analogous to native tri-leaflet heart valve shear 
stress distributions [25].  Indeed, the range of OSI (0.18 – 0.23) identified here is close-
to the typical OSI experienced by aortic valve tissues (OSI ~ 0.16) [41]. Previous studies 
on Flex-Flow conditions by [5] and [6] found that the 3-dimensional coupling of cyclic 
flexure, cyclic stretch and fluid-induced shear stresses manifest as oscillatory patterns 
surrounding the localized flow field of the heart valve leaflets. The flow patterns act on 
the leaflet surface as oscillatory shear stress.  Extensive evidence of oscillatory 
regulation of valvular gene regulation [7], particularly via Trpv4 and Trpp2 ionic 
channels [37], has previously been reported.  Thus, from a biomimetic standpoint, we 
interpret that the similarity in values we identified in the current study to the OSI of 
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native, healthy human aortic valves which maintains valve homeostasis, will enhance 
engineered valve tissue development and phenotype.  
     This study has several limitations and assumptions.  We only simulated the biofluid 
dynamics within 3 vascular locations.  Moreover, we did not consider the movement of 
the heart valve leaflets which is likely to alter specific OSI magnitudes.  There are some 
limitations associated with our bioreactor-derived OSI values from CFD; firstly, the FSF 
bioreactor that we used for the CFD portion of the current study has been shown to 
recapitulate the flow patterns experienced by the native tri-leaflet aortic valves[42, 25].   
Moreover, the averaged OSI across the entire aortic valve surface was previously 
reported to be an OSI ~0.16 [41] which is close to the “sweet spot” OSI range (0.18-
0.23) of the current study.  However, we note that fluid-induced oscillations are 
considerably greater on the fibrosa surface as compared to the ventricularis surface and 
as a result, regional OSI can vary.  The “sweet-spot” OSI range reported here and 
derived from FSF bioreactor CFD simulations, as well as the native aortic valve, 
represents averaged values for all surfaces and some differences between bioreactor 
versus native valve-OSI are bound to occur (~ 25%) and thus represents another 
limitation of this study.  Finally, we speculate that the biological responses of cells other 
than HBMSCs to the OSI “sweet-spot” or physiologically relevant window of OSI (0.18 
≤ OSI ≤ 0.23) may not be the same. Moreover, experiments reported herein were 
performed in monolayer culture and as a result, the extent to which cell-ECM, i.e. 3-
dimensional, interactions would be regulated by the “sweet-spot” OSI identified here is 
not known.  Nonetheless the current investigation does serve to demonstrate the relative 
distinctions between physiologically-induced OSI versus non-physiological counterparts 
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and established that the physiological range needed to promote valvular gene expression 
and HBMSC differentiation towards the valvular phenotype is narrow.  In addition, a 
specific OSI for stem-cell derived tissue engineering experiments using pulsatile flow 
mechanical conditioning was quantified here using a series of CFD simulations.  
Moreover, use of an OSI value (OSI = 0.23) taken from the sweet-spot OSI range (0.18 
≤ OSI ≤ 0.23) resulted in preferential valvular gene expression and phenotype in 
HBMSC culture experiments that were conducted in the current study. Thus, the OSI 
“sweet-spot” can now serve as a target for construct optimization for functional heart 
valve repair and/or replacement regenerative therapies.   
 
                                          4.  SPECIFIC AIM 2 
      Aortic valve calcification is a predominant cause for aortic insufficiency [43, 18, 
40].  While there are surgical treatment options available, they have distinct limitations 
and are generally performed when the native valve is already beyond repair. 
Additionally, pharmacological management of calcific valve disease during early stages 
is currently unavailable.  Therapeutic discoveries in the treatment of early stages of 
aortic valve calcification requires a fundamental understanding of cellular mechanisms 
that are regulated by both the local biochemical and biomechanical environments and 
have been the subject of extensive research.   
     From a biomechanics standpoint, fluid-induced shear stresses across the leaflets have 
been closely linked to normal and pathological valve tissue remodeling activity [41, 14, 
8, 10, 17, 16, 44], but specific shear stress patterns and magnitudes both spatial and 
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temporal have not yet been strongly linked to the underlying cell autocrine and paracrine 
signaling events that regulate the valve extracellular matrix (ECM).  Nonetheless, the 
incidence of low shear, disturbed laminar flow resulting in temporal blood flow 
oscillatory patterns on the fibrosa side of aortic valve leaflets has been shown to strongly 
correlate to regions of calcific nodule deposition and aggregation [10, 17].  The resulting 
oscillatory shear stresses (OSS) have thus been implicated in valve pathology [41, 45].  
We have previously shown that OSS promotes the formation of engineered heart valve 
tissues [5, 6, 12]. Collectively, the common theme in valve tissue engineering and 
calcification in the context of OSS is its association with active tissue remodeling 
activity.  However, the distinction between these scenarios may ultimately lie in the 
specific magnitude of oscillations that trigger the synthesis of healthy versus 
pathological valve ECM. Even less understood is the regional changes in fibrosa OSS 
that occur with aging. 
 As a first step in elucidating connections between OSS and calcification on the 
aortic valve surfaces, here, we took a computational approach to determine changes in 
OSS patterns on the human aortic valve fibrosa before and after calcific nodule 
deposition.  We subsequently compared these findings to regions of the fibrosa that did 
not develop any pathology. 
     4.1. Methodology for Specific Aim 2  
      All simulations in this study were carried out using commercially available software 
(ANSYS® Workbench 2016, Ansys Inc., Canonsburg, PA) within a Windows® 7 64-bit 
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Operating System environment (Microsoft Inc., Redmond, WA).  A workstation with 
dual processors was used to facilitate an efficient and accurate solution convergence 
(Intel Xeon® X5550, 2.66 GHz processor speed, Intel Inc., Santa Clara, CA).  
   Computed tomography (CT) reconstructions of a human aortic valve with and without 
severe calcification (Fig. 18a, b) were obtained (82-year old female; Valve-012 - 
HeartPrint catalog, Materialise Inc., Plymount MI). The temporal position of the valve 
structure depicted the early-diastolic phase wherein the leaflets would be in the process 
of closing.  The valve geometry without calcific nodules (fig. 18c) was first discretized 
utilizing a tetrahedral mesh density (1.70x103 nodes and 7.73x103 elements, fig. 18e).  
Calcified nodules were then placed as spatially determined from CT images to the 
healthy valve geometry (fig. 18d); as before, a tetrahedral mesh (4.89x104 nodes, 
2.63x105 elements, fig. 18f) was subsequently generated for the calcified valve.   
     The fluid was modelled as blood, using a viscosity and density of 3.5 centipoise and 
1.06 g/cm3, respectively. A no-slip boundary condition was applied to the entire 
geometry for each valve model.  Pulsatile flow simulations were run for the healthy and 
diseased aortic valve with solution convergence interpreted to have occurred when 
residuals arising from the continuity and momentum equations were able to meet a 
convergence criterion of 1 x 10-9.  
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Figure 18: (a) Healthy aortic valve Fibrosa geometry in early diastole, with left coronary cusp (LCC), 
right coronary cusp (RCC) and non-coronary cusp (NCC), before and (b) after calcification. (c)The 
simulated healthy valve fibrosa model and (d) its corresponding mesh, had calcified nodules (black) 
added across the leaflets for (e) the diseased valve model and (f) its corresponding mesh. Areas of 
interest (A1, A2, A3, A4) on those regions represented both calcified areas (A3) and unaffected areas of 
the diseased valve (A4) and the areas corresponding to the calcified regions (A1) and unaffected regions 
(A2) on the healthy valve. (h) On the diseased valve, calcified deposits were analyzed both 
independently and as a collective zone (area A3, black) [A3-NCC (126 mm2, located at distal belly of 
NCC), A3-RCC (117.2 mm2, located at tips and proximal belly of RCC) and A3-LCC (51.9 mm2, 
located at proximal belly of LCC)] along with the regions surrounding the deposits (area A4, red) [A4-
NCC: 194.3 mm2; A4-RCC: 203.6 mm2; A4-LCC: 240 mm2] within each specific cusp.  (g) The deposit 
regions corresponding to the diseased valve were then analyzed across the healthy valve (area A1, 
black) [A1-NCC: 144.93 mm2; A1-RCC: 81.08 mm2; A1-LCC:17.07 mm2] along with the areas 
consistent with the regions surrounding the deposits (area A2, red) [A2-NCC: 151.26 mm2; A2-RCC: 
218.16 mm2; A2-LCC:291.24 mm2]. 
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         4.1.1. Inlet and Outlet Boundary Conditions  
  An aortic waveform used in our previous aim and originally described by Lotz et al. 
[36] was prescribed to the inlet while an 80 mm Hg-pressure boundary condition was 
prescribed to the outlet.    
       4.1.2. Numerical Independence  
  Independence testing on both valve geometries was carried out to optimize the 
computational conditions as follows:  
        4.1.2.1. Mesh Independence  
       For the healthy valve geometry, an initial, fine tetrahedral mesh density 
of 6.67x104 nodes and 3.62x105 elements was used. After running through a steady state 
simulation of 30 iterations, an optimized tetrahedral mesh density of 1.70x103 nodes 
and 7.73x103 elements was determined after finding the averaged wall shear stress of the 
valve and surrounding anatomy was within 5% of the initial fine mesh. Subsequently, 
the diseased valve was assigned an initial, fine tetrahedral mesh density 
of 1.21x105 nodes and 6.69x105 elements. An optimized tetrahedral mesh density 
of 4.89x104 nodes and 2.63x105 elements was determined, using a steady state 
simulation of 30 iterations, to find the averaged wall shear stress of the valve and 
surrounding anatomy, similarly was within 5% of its initial, fine mesh valve.  
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     4.1.2.2. CFL-timestep selection and subsequent CFD model validation  
      For both valve geometries utilized, the Courant-Friedrichs-Lewy condition was 
satisfied with a Courant number <1 for a timestep of 1 ms [46]. In addition, with the 80 
mm Hg outlet condition satisfied, both healthy and diseased valve geometries exhibited 
a computed average inlet pressure of within 5% of a physiologically realistic value of 
120 mm Hg.  
       4.1.2.3. Cyclic Independence  
     Three cycles were prescribed to the inlet of each valve geometry. The healthy valve 
model had an error of 2% between the 1st and 3rd cycles and 1.7% between the 2nd and 
3rd cycle. The diseased valve had an error of 14.9% between the 1st and 3rd cycle 
and 1.7% between the 2nd and 3rd cycle. Ultimately, the 3rd cycle was selected for 
analysis in the healthy valve model and the diseased valve model.  
4.2. Results of Specific Aim 2 
   4.2.1. Time-Averaged Shear Stress 
The spatial distributions of axial time-averaged wall shear stresses (TAWSS) were 
presented on the healthy valve (Fig. 19a) and diseased valve (Fig. 19c).  
      4.2.1.1. Healthy Valve Model 
  The ventricularis side of the valve (fig. 20a) had an average (± SEM) axial shear stress 
of 1.25 ± 0.0195 dynes/cm2. As expected, the distribution of the shear stresses on the 
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fibrosa side was relatively low in magnitude. The maximum axial shear stresses on the 
valve were concentrated at the leaflet tips while minimum, negative shear stresses were                      
 
Figure 19: Healthy Valve spatial distribution of axial time-averaged wall shear stresses (a, 
mean: 0.091 dynes/cm2) and OSI (b, mean: 0.0998). Calcified Valve spatial distribution of 
axial time-averaged wall shear stresses (c, mean: 0.323 dynes/cm2) and OSI (d, mean: 0.1557). 
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predominantly located across the fibrosa LCC. The mean fibrosa axial stress value of the 
valve was 0.091± 0.067 dynes/cm2. 
      4.2.1.2. Calcified Valve Model 
   The ventricularis side of the valve (fig. 20c) exhibited an average axial shear stress 
average (± SEM) of 1.95 ± 0.001 dynes/cm2. Maximum shear stresses were, as in the 
case of the healthy valve, located at the leaflet tips. Minimum, negative stresses were 
concentrated at the surface of the LCC (fig. 19c). The average fibrosa axial shear stress 
value of the valve was 0.32 ± 0.004 dynes/cm2. 
Fig. 20: Healthy ventricularis geometry plots of (a) axial time-averaged wall shear stress 
(TAWSS) (mean: 1.25 dynes/cm2) and (b) OSI (mean: 0.003457) as well as diseased 
ventricularis geometry plots for (c) axial TAWSS (mean: 1.95 dynes/cm2) and (d) OSI 
(mean: 0.01) 
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  4.2.2. Oscillatory Shear Index 
The spatial distributions of OSI were computed for the healthy valve (Fig. 19b) and 
diseased valve (Fig. 19d) cases; averaged OSI values were subsequently summarized 
(Table 3, Table 4). OSI of Cusp-designated regions A1 – A4 (Fig. 18g-18h) were also 
reported (Table 3) with the following observations: 
    4.2.2.1. Healthy Valve Model 
  OSI on the ventricularis side of the valve was negligible (fig. 20b, mean OSI = 0.004). 
On the other hand, on the fibrosa side, the OSI was relatively much higher on the RCC 
(OSI = 0.147) while the NCC had an averaged OSI of 0.060 and the LCC had an OSI of 
0.027. The OSI average of the entire fibrosa side was computed to be OSI = 0.103. 
4.2.2.2. Calcified Valve Model 
   Similar to the healthy valve, the OSI on the ventricularis side of the valve was 
substantially lower than that of the fibrosa (fig. 20d, mean OSI =0.010). The OSI field 
across the LCC (plaque area: 5.23%; mean OSI =0.211; Table 2) had a distinct, non-
uniform distribution with high OSI regions surrounding the calcified deposit on its 
surface (fig. 19d). Additionally, the RCC (plaque area: 39.8%) and the NCC (plaque 
area: 38.2%) exhibited a mean OSI of 0.131 and 0.051, respectively. The OSI of the 
entire fibrosa side was computed to be 0.156. 
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4.2.2.3.  Regions that developed calcification 
     Regions that developed calcification, A3 on the NCC, RCC and LCC, had mean OSIs 
of 0.06, 0.101, and 0.108 respectively with the collective OSI of these regions (area A3, 
Fig. 18h) exhibiting an overall Mean ± SEM OSI: 0.089 ± 0.015. The corresponding 
regions of A3 on the healthy valve were 0.009, 0.232, and 0.023 with the mean OSI of 
these regions (area A1, Fig. 18g): 0.088 ± 0.0721. The unaffected regions surrounding 
A3 on the NCC, RCC and LCC had OSIs of 0.0267, 0.1522, and 0.2411, respectively, 
with the mean OSI of these regions (area A4, Fig. 18h): 0.14 ± 0.0622. Corresponding 
regions for A4 on the healthy valve had OSIs of 0.05, 0.215, and 0.044 with a mean OSI 
of these regions (area A2, Fig. 18g): 0.103 ± 0.056. 
4.2.3. %Change in OSI 
    The percent decrease in OSI (Table 4) in the region of the calcified valve (A3) 
compared to the same location when it was not diseased (A1) was found to be marginal 
(1.59%). On the other hand, the regions that remained unaffected by calcification on 
both valves (A2, A4) had a much more substantial decrease in OSI by 35. 9%.  
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Aortic Valve Side Healthy OSI Diseased OSI Plaque 
Percentage 
Ventricularis 0.0035 0.01 0% 
NCC 0.0603 0.0393 38.2% 
LCC 0.0268 0.2114 5.23% 
RCC 0.1472 0.1310 39.8% 
 
Calcified Region A1 A2 A3 A4 
NCC 0.009 0.05 0.0597 0.0267 
LCC 0.232 0.215 0.1009 0.1522 
RCC 0.023 0.044 0.1077 0.2411 
Mean± SEM 0.088 ± 0.0721 0.103 ± 0.056 0.0894 ± 0.015 0.14 ± 
0.0622 
 
%Change 
(Mean A1 & 
Mean A3) 
%Change 
(Mean A2 & 
Mean A4) 
%Change of 
mean OSI in 
NCC 
%Change of 
mean OSI in 
RCC 
%Change 
of mean 
OSI in 
LCC 
1.59 (SD: 1.12, 
SEM:0.80) 
35.9 (SD: 25.4, 
SEM:18) 
34.8  11.0 
  
688.0 
  
 
 
Table 4: Percent (%) change in mean OSI of cusp-designated regions and in mean OSI across distinct 
valvular cusps. There was a markedly low percent change between the means of A1 and A3 (1.6 %) 
compared to the change between the means of A2 and A4 (36%).   
9  
 
Table 3: OSI on cusp-designated areas of valve fibrosa (A1-A4) for each region. Note that A3 and 
A4 are the calcified regions and unaffected regions of the calcified valve, respectively, while A1 and 
A2 are the corresponding calcified regions and corresponding unaffected regions on the healthy 
valve.   Mean ± SEM is provided for each area. A slight shift in OSI (1.6%) occurred between the 
means of A1 and A3.   
 
Table 2: Healthy and diseased OSI on both ventricularis and fibrosa sides of valve with percent of 
calcified plaque occupying each cusp. Particularly, there was a significant change in OSI between the 
diseased and healthy LCC (p < 0.05). 
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4.3. Discussion of Specific Aim 2 
     Axial TAWSS results from both affected and unaffected regions of both valve 
models (Fig. 19a, 19c) revealed non-unidirectional flow existed across the fibrosa, 
demonstrating that the native valve environments could produce OSS. The computed 
shear stresses of the aortic valve model simulated here had values [-5.94 dynes/cm2 - 
54.7 dynes/cm2] within the ranges previously reported in the literature [11, 30, 17, 16] 
with relatively lower shear stresses found on the fibrosa side (mean: 0.091 dynes/cm2) 
compared to the ventricularis side of each model (mean:1.25 dynes/cm2).  
    The aortic valve OSI environment shifted remarkably between healthy and diseased 
valve physiologies.  Consistent with previous work [48, 47, 17], our findings 
demonstrated that the NCC and RCC were the most susceptible to calcification. The 
healthy valve OSI for the NCC (OSI mean: 0.060), RCC (mean: 0.131) and LCC (mean: 
0.027) established that OSI across a healthy valve geometry could vary between the 
three aortic valve leaflets; the diseased valve OSI of the NCC (OSI mean: 0.039), RCC 
(mean: 0.147) and LCC (mean: 0.211) similarly also varied.  These findings suggest that 
relative changes in OSI or lack thereof between healthy and valve pathologies could 
potentially be used to predict regions on the valve fibrosa prone to calcification.  
Specifically, we speculate that in situations where the rate of valve matrix remodeling 
slows down, a change in OSI is unlikely, in time, making the valve susceptible to 
triggering abnormal ECM synthesis. The current study was able to confirm that indeed, 
regions susceptible to high calcification had only marginal changes in the OSI (healthy 
tissue area, A1: Mean ± SEM: 0.088 ± 0.072 and same tissue area A1, after calcification, 
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i.e., A3: Mean ± SEM: 0.089 ± 0.015), resulting in a % change in OSI of only 1.59%). 
Conversely, regions of the aortic valve that did not get calcified, i.e. A2 and later, A4, 
exhibited a rather substantial % change in OSI of nearly 36%. We interpret that regional 
ECM remodeling of the fibrosa, particularly in the primary ECM components of the 
valve, i.e., collagen, glycosaminoglycans, and elastin, alter the valve shape which will 
change the OSI as would be expected in the localized leaflet surface environment.  
However, when this remodeling does not occur or occurs slower than needed, the OSI 
does not change, potentially triggering a disease pathway.  In particular, since aortic 
valve calcification is strongly correlated with the aging process, it is likely that the slow 
turnover of elastin remodeling in the valve may be primarily associated with changes in 
OSI that occurs over decades, and leads to pathologies later in life, as recent studies 
have similarly suggested [53, 50, 54, 8, 49, 51, 11, 43, 52, 10] 
    The findings in this brief report are very preliminary and contain two major 
limitations in the approaches. Firstly, a single patient’s valve was analyzed before and 
after calcification. Secondly, the flow physics in a pulsatile flow model without 
accounting for valve leaflet motion was simulated during the early-diastolic, closing 
phase of the valve.  While the absolute OSI values would be very different from those 
uncovered here, the general trend that negligible longitudinal changes in OSI co-relate 
with a higher probability of disease due to insufficient valve ECM remodeling, is likely 
to hold. Thus, in conclusion, we present in these short communications, a new 
interpretation of OSI in the context of valve tissue remodeling.  In cases of tissue 
regeneration, a set value of OSI may be targeted to promote de novo tissue growth in-
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vitro as we previously described in aim 1.  However, when the OSI remains relatively 
unchanged in the native aortic valve fibrosa environment, this may be suggestive of an 
absence of or insufficient valve ECM remodeling, which could lead to a triggering point 
for valve pathologies.  Therefore, in addition to the OSI environment, a change in the 
longitudinal and regional leaflet, fibrosa-side OSI conditions with aging, or lack thereof 
may serve useful as a bio-marker (e.g. a % change in OSI computed every 5 years after 
the age of 40) for the early detection of aortic valve calcification. 
 
            
                                                5. CONCLUSION 
   Through utilization of a computational approach, the results included in this thesis 
have demonstrated the application and significance of oscillatory flow, namely OSS, 
within heart valve tissue engineering and heart valve disease. Specifically, these results 
have shown that physiologically relevant OSI environments can produce an optimized 
phenotype for BMSC-derived engineered valve tissue. Pulsatile conditions that produce 
an OSI within the “sweet spot” range (0.18≤ OSI≤ 0.23) can now be used in bioreactor 
designs for proper conditioning of TEHVs. Furthermore, results have additionally 
established the method of using changes in OSI in detecting aortic valve remodeling that 
predispose native valve tissue towards higher probabilities of leaflet calcification. 
Current efforts are focused on in-vitro experiments that will provide quantifiable data to 
further support our findings. 
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